Adverse Effects Induced by Osimertinib Based on the Dose per Body Constitutional Parameters: A Retrospective Observational Study
Author:
Nagamizu Masaya12, Hotta Yuji134, Morozumi Issei2, Nakamura Daigaku4, Hori Masayuki4, Otsuka Yuto4, Takemoto Ryuhei4, Horita Yasuhiro34, Wakita Eri5, Morishita Nobuyuki2, Kondo Masahiro35, Furukawa‐Hibi Yoko34, Kimura Kazunori134
Affiliation:
1. Department of Hospital Pharmacy, Nagoya City University Graduate School of Pharmaceutical Sciences 2. Department of Pharmacy, Nagoya City University West Medical Center 3. Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences 4. Department of Pharmacy, Nagoya City University Hospital 5. Department of Pharmacy, Nagoya City University East Medical Center
Publisher
Pharmaceutical Society of Japan
Reference42 articles.
1. 1) Shi Y, Wu L, Yu X, Xing P, Wang Y, Zhou J, Wang A, Shi J, Hu Y, Wang Z, An G, Fang Y, Sun S, Zhou C, Wang C, Ye F, Li X, Wang J, Wang M, Liu Y, Zhao Y, Yuan Y, Feng J, Chen Z, Shi J, Sun T, Wu G, Shu Y, Guo Q, Zhang Y, Song Y, Zhang S, Chen Y, Li W, Niu H, Hu W, Wang L, Huang J, Zhang Y, Cheng Y, Wu Z, Peng B, Sun J, Mancao C, Wang Y, Sun L. Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3). Cancer Commun. (Lond.), 42, 1314–1330 (2022). 2. 2) Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin MC, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, Soria JC. FLAURA Investigators. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N. Engl. J. Med., 382, 41–50 (2020). 3. 3) Hanna N, Johnson D, Temin S, Baker S Jr, Brahmer J, Ellis PM, Giaccone G, Hesketh PJ, Jaiyesimi I, Leighl NB, Riely GJ, Schiller JH, Schneider BJ, Smith TJ, Tashbar J, Biermann WA, Masters G. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J. Clin. Oncol., 35, 3484–3515 (2017). 4. 4) Takiguchi T. Guidelines for Diagnosis and Treatment of the Lung Cancer/Malignant Pleural Mesothelioma/Thymic Tumors 2022. Tokyo: Kanehara & Co., Ltd.; 2022. 5. 5) Jia Y, Lacouture ME, Su X, Wu S. Risk of skin rash associated with erlotinib in cancer patients: a meta-analysis. J. Support. Oncol., 7, 211–217 (2009).
|
|